Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Brazil, US Resume Tariff Talks as Trade Tensions Persist 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
India Manufacturing Growth Slows to Five-Year Low in August 
Bessent Says Yen Moves Contained as BOJ Rate Decision Looms 
Canada Backs €100 Billion Global Defence Bank 
Bessent Urges Japan on Fiscal Discipline, BOJ Rate Hikes 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Asian Currencies Mixed as Yen Nears 160, Oil Surges 
Asian Stocks Slip as Fed Rate Hike Bets and Oil Surge Weigh 
Asian Tech Stocks Slide as Fed Rate Hike Bets Rise 
Gold Prices Steady as U.S.-Iran Tensions Lift Inflation Risks 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Ukraine Sanctions Chief Heads to Washington to Push Russia Bill 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Add as a preferred source on Google
Hyundai Pharmaceutical revealed on Tuesday, July 6, that it has submitted an application so it can start selling its abortion pill in South Korea. The company filed for authorization to market at the Ministry of Food and Drug Safety.
Hyundai Pharm is intending to start selling its Mifegymiso that is composed of four tablets of misoprostol and one tablet of mifepristone. Mifepristone is being sold in Korea under the brand name Mifegyne.
First legal abortion pill in S. Korea
According to The Korea Herald, if the ministry will give a go signal for the sale of Mifegymiso, it would effectively become the very first abortion pill that will be legally marketed in the country. In 2019, the Constitutional Court reversed the ban on abortion in the first 14 weeks of pregnancy, so this paved the way for the pills to be produced.
Hyundai Pharm will be distributing Mifegymiso to the market as a prescription drug. This means that only patients with proper medical advice from health professionals will be able to obtain the drug. Without the supervision of a certified health advisor, an individual will not be allowed to purchase the abortion pill.
The U.S. Food and Drug Administration stated that abortion pills are safe to use in the first nine or 10 weeks of pregnancy. While it seems that more and more groups are supporting and even promoting abortion pills, it was reported that the National Assembly is working on revising the Pharmaceutical Affairs Act so it can bar the advertising of the drug.
The marketing license for Mifegymiso
Korea Biomedical Review reported that Hyundai Pharm’s filing for approval for the abortion drug has gained attention because the Ministry of Health and Welfare already granted repayment for doctor’s education and counseling sessions about medical abortion.
The policy asks doctors to give educational counseling to pregnant women regarding abortion. They are allowed to explain the procedures for abortion, including precautions before and after the surgery. The physicians will also be taught about the physical and mental complications of abortion and contraception.
Meanwhile, Hyundai Pharm stated it will do its best to gain approval. “We will closely work with the drug developer to accelerate the regulatory nod for the drug,” a company official said.
